Nisa Investment Advisors LLC Has $287,000 Stock Position in Insmed, Inc. (NASDAQ:INSM)

Nisa Investment Advisors LLC raised its stake in Insmed, Inc. (NASDAQ:INSM) by 6.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,761 shares of the biopharmaceutical company’s stock after buying an additional 228 shares during the period. Nisa Investment Advisors LLC’s holdings in Insmed were worth $287,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Elequin Capital LP acquired a new stake in Insmed in the fourth quarter valued at approximately $28,000. Steward Partners Investment Advisory LLC boosted its position in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 163 shares in the last quarter. NBC Securities Inc. acquired a new stake in Insmed in the first quarter valued at approximately $49,000. Versant Capital Management Inc boosted its position in Insmed by 546.3% in the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 590 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Insmed by 62.0% in the first quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 386 shares in the last quarter.

Insmed Trading Up 1.7%

INSM opened at $104.59 on Thursday. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $106.83. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. The company has a market cap of $19.84 billion, a P/E ratio of -17.58 and a beta of 0.90. The company has a fifty day moving average price of $85.41 and a two-hundred day moving average price of $78.02.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The company had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. During the same period last year, the firm posted ($1.06) earnings per share. The company’s revenue for the quarter was up 22.9% on a year-over-year basis. Analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on INSM. The Goldman Sachs Group lifted their price target on shares of Insmed from $100.00 to $112.00 and gave the stock a “buy” rating in a report on Wednesday, June 11th. Bank of America lifted their price target on shares of Insmed from $94.00 to $109.00 and gave the stock a “buy” rating in a report on Wednesday, June 11th. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $90.00 to $111.00 and gave the stock an “overweight” rating in a report on Tuesday, July 8th. Royal Bank Of Canada lifted their price target on shares of Insmed from $99.00 to $106.00 and gave the stock an “outperform” rating in a report on Wednesday, June 11th. Finally, HC Wainwright lifted their price target on shares of Insmed from $90.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, June 11th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and an average price target of $108.07.

Insider Transactions at Insmed

In other Insmed news, CEO William Lewis sold 6,830 shares of Insmed stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $102.37, for a total value of $699,187.10. Following the completion of the sale, the chief executive officer directly owned 233,924 shares of the company’s stock, valued at approximately $23,946,799.88. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael Alexander Smith sold 933 shares of Insmed stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $102.51, for a total transaction of $95,641.83. Following the completion of the sale, the insider directly owned 66,394 shares of the company’s stock, valued at approximately $6,806,048.94. This trade represents a 1.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 548,197 shares of company stock valued at $49,124,834. 3.00% of the stock is owned by insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.